1. Barry Mj et al. J Urol 1992;148:1549-57 2. Nickel JC et al. CMAJ 1996; 155:1251-9 3. Aldridge S. Lancet 1996;348:602 4. Roehrborn CG et al. J Urol 2004; 171(3): 1194-98 5. McConnell JD et al. N Engl J Med 2003; 349:2387-98 6. Kirby RS et al. Urology 2003; 61:119-126 7. Wilt TJ et al. BJU International 2002; 89:214-225 8. Edwards JE et al. BMC Urology 2002; 2:14 9. Ramsey EW et al. J Urol 2000; 163:499 10. Boyle P et al. Urology 2000; 55:533 11. Yang et al. Journal of Urology 2001; 165:1526 12. Roehrborn CG et al. Urology 2002; 60:434 13. Hoffman RM et al. Urology 2003;169:210 14. Djavan B et al. Journal of Endourology 2000; 14:661 15. Ransey EW et al. Journal of Endourology 2000; 14:671 16. Ipertrofia prostatica benigna. Data della ricerca luglio 2003. Clinical Evidence, 3° Ed. Italiana. In http://aifa.ecce.minsa.it/ 17. Bent S et al. Saw Palmetto for Benign Prostatic Hyperplasia. N Engl J Med 2006 Feb 9; 354: 557-566 18. Patel AK et al. Benign prostatic hyperplasia: treatment in primary care. BMJ 2006 Sept 9; 333: 535-539 19. Roehrborn CG et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008 Feb; 179:616.
|
|
